OCGN
NASDAQOcugen Inc.
News · 26 weeks61-12%
2026-03-012026-08-23
Mix2590d
- SEC Filings9(36%)
- Other8(32%)
- Insider6(24%)
- Earnings2(8%)
Latest news
25 items- PROcugen to Participate in Upcoming September Investor and Industry ConferencesMALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026. Citi 2026 Biopharma Back to School ConferenceLocation: JW Marriott Essex House, New York City, NYDate: Wednesday, September 9, 2026Time: 3:40–4:15 p.m. ETFormat: Fireside ChatPresenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen H.C. Wainwright 28th Annual Global Investment ConferenceLocation: Lotte New York Palace, New York City, NY Date: T
- SECSEC Form DEFA14A filed by Ocugen Inc.DEFA14A - Ocugen, Inc. (0001372299) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ocugen Inc.SCHEDULE 13G/A - Ocugen, Inc. (0001372299) (Subject)
- SECSEC Form SCHEDULE 13G filed by Ocugen Inc.SCHEDULE 13G - Ocugen, Inc. (0001372299) (Subject)
- SECSEC Form 10-Q filed by Ocugen Inc.10-Q - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen Provides Business Update with Second Quarter 2026 Financial ResultsConference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to initiate Phase 3 this quarterGranted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA for OCU410, enabling eligibility for priority review and accelerated approvalSigned a binding term sheet with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, to negotiate an exclusive license for OCU400 in retinitis pigmentosa (RP) across the Middle East and North Africa (MENA) regionSuccessfully completed OCU400 Process Per
- PROcugen to Participate in Upcoming August Investor ConferencesMALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor conferences in August 2026. Oppenheimer 4th Annual Biotech in the Berkshires Summit Location: Miraval Resort, Lenox, MADate: Tuesday, August 4, 2026Time: 12:30–1:10 p.m. ETSession Title: Beyond the Readout: Building Durable Value in Rare Diseases & Gen MedsFormat: Panel discussionPanelists: Shankar Musunuri, Pratik Shah, Ram Aiyar, Frank Gleeson, Allan ReineModerators: Leland Gershell, Managin
- SECSEC Form DEFA14A filed by Ocugen Inc.DEFA14A - Ocugen, Inc. (0001372299) (Filer)
- SECSEC Form DEF 14A filed by Ocugen Inc.DEF 14A - Ocugen, Inc. (0001372299) (Filer)
- PROcugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular DegenerationRMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet needThe designation could accelerate OCU410’s regulatory path while further differentiating its one-time treatment for life approach from current therapies requiring chronic administration MALVERN, Pa, July 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to Ocugen’s investigational product OCU410 for the treatment of geog
- PROcugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial ResultsMALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s second quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 6, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 2222566Webcast: Available on the events section of the Oc
- SECSEC Form PRE 14A filed by Ocugen Inc.PRE 14A - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaCumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region. Purs
- PROcugen to Participate in Upcoming July Industry ConferencesMALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026. Piper Sandler Virtual Ophthalmology Day – Fireside Chat Date: Friday, July 10, 2026Time: 10:00–10:25 a.m. EDTSpeaker: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, OcugenModerator: Biren Amin, Managing Director, Healthcare Equity Research, Piper Sandler & Co. OIS (Ophthalmology Innovation Source) Retina Innovation Summit Location: DoubleTree MontrealDate
- INSIDERChief Financial Officer Johnson-Greene Treerita Essalima bought $25,830 worth of shares (21,000 units at $1.23), increasing direct ownership by 4% to 521,000 units (SEC Form 4)4 - Ocugen, Inc. (0001372299) (Issuer)
- INSIDERSEC Form 4 filed by Director Kompella Uday4 - Ocugen, Inc. (0001372299) (Issuer)
- INSIDERSEC Form 4 filed by Director Chandrasekhar Satishchandran4 - Ocugen, Inc. (0001372299) (Issuer)
- INSIDERSEC Form 4 filed by Director Castillo Kirsten4 - Ocugen, Inc. (0001372299) (Issuer)
- INSIDERSEC Form 4 filed by Director Zhang Junge4 - Ocugen, Inc. (0001372299) (Issuer)
- INSIDERSEC Form 4 filed by Director Coleman Blaise4 - Ocugen, Inc. (0001372299) (Issuer)
- SECOcugen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events8-K - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Leadership Update8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen to Participate in Upcoming June Investor and Industry ConferencesMALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026. Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference Date: Thursday, June 4, 2026 Time: 2:30pm EDT Clinical Trials at the Summit 2026 Location: Fontainebleau Las VegasDate: Saturday, June 13, 2026Time: 10:19 – 10:39 am PDTInherited Retinal Diseases: Transforming the Future Through InnovationModerator: Peter KaiserPanelists: Lance Baldo, Pau
OCGN FAQ
7 questionsWhat does Ocugen Inc. do?
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema...Where does OCGN stock trade?
Ocugen Inc. (OCGN) is listed on NASDAQ.What sector and industry is OCGN in?
Ocugen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Ocugen Inc. go public?
Ocugen Inc. (OCGN) completed its IPO in 2014.What are analysts saying about OCGN?
Ocugen Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $1200.00 price target on 2026-03-17. Recent price targets range from $350.00 to $1200.00.What companies are similar to OCGN?
Notable peers in the same industry include ISEE (IVERIC bio Inc.), CTIC (CTI BioPharma Corp. (DE)), OTLK (Outlook Therapeutics Inc.), GOSS (Gossamer Bio Inc.), BXRX (Baudax Bio Inc.). Compare OCGN side-by-side with any of them on Quantisnow.How can I track OCGN on Quantisnow?
Quantisnow aggregates Ocugen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OCGN to receive live email and push alerts on every new disclosure.